A. A. Shilovskaya
Research Subjects
A. A. Shilovskaya has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- D. D. Dolgih
Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky
2 shared publications - E. V. Shaposhnikova
Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky
2 shared publications - M. I. Bazina
Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky
2 shared publications - N. A. Semenova
Krasnoyarsk Regional Center for Maternal and Child Health No. 2
2 shared publications
Latest Publications
- Open Access
- 31 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- Vol. 20 (5) , 112-118
Efficacy and safety of iron supplements in the treatment of anemia in pregnant women
Introduction. Therapy for iron deficiency conditions that complicate pregnancy, childbirth, and the postpartum period is always considered from the standpoint of the relationship between the safety and effectiveness of the medication, forming the patient’s commitment to long-term treatment. Aim. To analyze the therapeutic efficacy, clinical tolerance and perinatal outcomes when using a ferrous sulfate medication and Ascorbic acid in the treatment of iron deficiency anemia (IDA) in pregnant women. Materials and methods. The study included 61 women diagnosed with mild IDA in the first half of pregnancy (main group). The medication for treatment of Iron deficient anemia was used Sorbifer Durules (iron sulfate 100 mg Fe 2+ and Ascorbic acid 60 mg) 100 mg two times per day, until the normalization of hematological parameters and improvement of the clinical picture, with a transition to 100 mg per day until delivery to prevent IDA. The control group included 43 pregnant women without IDA. Results. The gestational age included in the observation was 14.9 (3.9) weeks. The positive dynamics were revealed an increase in hemoglobin levels by 6.3 g/l (p < 0.05) after one month of the therapy with further increase in hemoglobin at the end of the third trimester of pregnancy (36.9 ± 1.0 week) by 10.4 g/l (p < 0.05). A decrease in hemoglobin levels to 109.2 ± 6.5 and 114.1 ± 8.4 g/l was noted in patients of the main and control groups after delivery, while maintaining average parameters within the physiological values for the first week of the postpartum period (more than 100 g/l). Adverse events during treatment were recorded in 4.9% of pregnant women; there were no clinical cases requiring cessation of medication. Conclusion. Clinical data and hematological parameters during therapy with a combination of Ferrous sulfate and Ascorbic acid in an extended-release formula (Sorbifer Durules) in pregnant women demonstrated good tolerance and efficacy in the treatment of iron deficiency anemia.
- 31 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- Vol. 20 (5) , 112-118
Open AccessEfficacy and safety of iron supplements in the treatment of anemia in pregnant women
Introduction. Therapy for iron deficiency conditions that complicate pregnancy, childbirth, and the postpartum period is always considered from the standpoint of the relationship between the safety and effectiveness of the medication, forming the patient’s commitment to long-term treatment. Aim. To analyze the therapeutic efficacy, clinical tolerance and perinatal outcomes when using a ferrous sulfate medication and Ascorbic acid in the treatment of iron deficiency anemia (IDA) in pregnant women. Materials and methods. The study included 61 women diagnosed with mild IDA in the first half of pregnancy (main group). The medication for treatment of Iron deficient anemia was used Sorbifer Durules (iron sulfate 100 mg Fe 2+ and Ascorbic acid 60 mg) 100 mg two times per day, until the normalization of hematological parameters and improvement of the clinical picture, with a transition to 100 mg per day until delivery to prevent IDA. The control group included 43 pregnant women without IDA. Results. The gestational age included in the observation was 14.9 (3.9) weeks. The positive dynamics were revealed an increase in hemoglobin levels by 6.3 g/l (p < 0.05) after one month of the therapy with further increase in hemoglobin at the end of the third trimester of pregnancy (36.9 ± 1.0 week) by 10.4 g/l (p < 0.05). A decrease in hemoglobin levels to 109.2 ± 6.5 and 114.1 ± 8.4 g/l was noted in patients of the main and control groups after delivery, while maintaining average parameters within the physiological values for the first week of the postpartum period (more than 100 g/l). Adverse events during treatment were recorded in 4.9% of pregnant women; there were no clinical cases requiring cessation of medication. Conclusion. Clinical data and hematological parameters during therapy with a combination of Ferrous sulfate and Ascorbic acid in an extended-release formula (Sorbifer Durules) in pregnant women demonstrated good tolerance and efficacy in the treatment of iron deficiency anemia.
- Open Access
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 87-94
Iron deficiencyanemia and pregnancy: Treatment options
Introduction . The choice of medications for the treatment of iron deficiency anemia (IDA) in a pregnant woman is based on therapeutic efficacy and safety, forming a high patient compliance to long-term therapy Aim . To evaluate the therapeutic efficacy, clinical tolerance and safety of using a medication based on iron sulfate and ascorbic acid in the treatment of iron deficiency anemia in pregnant women Materials and methods . The study included 155 women diagnosed with IDA: twenty-four pregnant women in the first trimester (group 1), forty-five pregnant women in the second trimester (group 2), and eighty-six patients in the third trimester (group 3). Antianemic therapy was administered to all pregnant women with Sorbifer Durules (iron sulfate 100 mg of iron sulfate and 60 mg of ascorbic acid) 100 mg two times per day for a long time until normalization of hematological parameters and improvement of the clinical symptoms with a transition to 100 mg per day until delivery for the purpose of preventing IDA. Results. The gestational age included in the observation were 10.6 (1.6), 20.2 (2.6) and 30.9 (2.6) weeks. When analyzing hematological parameters changes in 1 month after the start of therapy, there was positive dynamic which revealed the increase in hemoglobin levels by 5.4 g/l and 7.2 g/l in patients of groups 1 and 2, respectively (p < 0.05), with a continuing tendency to increase at 37.1 ± 1.1 weeks by 10.3 g/l and 9.7 g/l (p < 0.05). It was noted that there was a decrease in the number of patients with IDA in group 1to 20.8%, which is 1.5 and 2.1 times lower compared to groups 2 and 3 (p = 0.03). Adverse reactions when taking Sorbifer Durules were registered in 3.2% of pregnant women, there were no clinical situations requiring discontinuation of the medication. Conclusion. The combination of iron sulfate and ascorbic acid in a prolonged release formula (Sorbifer Durules) is a well-tolerated and effective treatment option of IDA at any stage of pregnancy.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 87-94
Open AccessIron deficiencyanemia and pregnancy: Treatment options
Introduction . The choice of medications for the treatment of iron deficiency anemia (IDA) in a pregnant woman is based on therapeutic efficacy and safety, forming a high patient compliance to long-term therapy Aim . To evaluate the therapeutic efficacy, clinical tolerance and safety of using a medication based on iron sulfate and ascorbic acid in the treatment of iron deficiency anemia in pregnant women Materials and methods . The study included 155 women diagnosed with IDA: twenty-four pregnant women in the first trimester (group 1), forty-five pregnant women in the second trimester (group 2), and eighty-six patients in the third trimester (group 3). Antianemic therapy was administered to all pregnant women with Sorbifer Durules (iron sulfate 100 mg of iron sulfate and 60 mg of ascorbic acid) 100 mg two times per day for a long time until normalization of hematological parameters and improvement of the clinical symptoms with a transition to 100 mg per day until delivery for the purpose of preventing IDA. Results. The gestational age included in the observation were 10.6 (1.6), 20.2 (2.6) and 30.9 (2.6) weeks. When analyzing hematological parameters changes in 1 month after the start of therapy, there was positive dynamic which revealed the increase in hemoglobin levels by 5.4 g/l and 7.2 g/l in patients of groups 1 and 2, respectively (p < 0.05), with a continuing tendency to increase at 37.1 ± 1.1 weeks by 10.3 g/l and 9.7 g/l (p < 0.05). It was noted that there was a decrease in the number of patients with IDA in group 1to 20.8%, which is 1.5 and 2.1 times lower compared to groups 2 and 3 (p = 0.03). Adverse reactions when taking Sorbifer Durules were registered in 3.2% of pregnant women, there were no clinical situations requiring discontinuation of the medication. Conclusion. The combination of iron sulfate and ascorbic acid in a prolonged release formula (Sorbifer Durules) is a well-tolerated and effective treatment option of IDA at any stage of pregnancy.